Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran

Iranian Journal of Microbiology

Volumn 7, Issue 2, 2015, Pages 109-117

  Solgi, Ghasem ^a   Ghannad, Masoud Sabouri ^a   Khalilian, Alireza ^a   Majlesi, Amir ^a   Hajiloo, Mehrdad ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibody; Epidemiology; Genotype; HCV

Indexed keywords

ADULT; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUESTIONNAIRE; VIRUS LOAD;

HEPATITIS C VIRUS;

EID: 84930448798     PISSN: 20083289     EISSN: 20084447     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Attaullah S, Khan S, Ali I. Hepatitis c virus genotypes in pakistan: A systemic review. Virol J 2011;8:433.
2. Howard CR. Hepatitis c virus: Clades and properties. J Gastroenterol Hepatol 2002;17 Suppl:S468-470.
3. Ripoli M, Pazienza V. Impact of hcv genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-759.
4. Rolfe KJ, Curran MD, Alexander GJ, Woodall T, Andrews N, Harris HE. Spontaneous loss of hepatitis c virus rna from serum is associated with genotype 1 and younger age at exposure. J Med Virol 2011;83:1338-1344.
5. Guido M, Rugge M, Thung SN, Chemello L, Leandro G, Alberti A, et al. Hepatitis c virus serotypes and liver pathology. Liver 1996;16:353-357.
6. Nakamura H, Kako M, Aikawa T, Mayumi M, Kanai K. [HCV-serotype and ifn response]. Nihon Rinsho 1994;52:1734-1737.
7. Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of pakistani patients infected with hepatitis c virus type 3. Int J Infect Dis 2002;6:272-276.
8. Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis c virus genotypes in 2231 patients in iran. Hepatol Res 2007;37:101-103.
9. Kabir A, Alavian SM, Keyvani H. Distribution of hepatitis c virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: A preliminary study. Comp Hepatol 2006;5:4.
10. Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepatitis Monthly 2013;13(1):e7991.
11. Vahdat K, Keyvani H, Tabib SM, Rostamabadi S, Valizadeh SM, Cheraghi S, Shamsian S, Zandi K. Molecular epidemiology of hepatitis c virus genotypes in Bushehr province, Iran. Eur Rev Med Pharmacol Sci 2010;14:861-864.
12. Feyznezhad R, Behzadi MA, Yaghobi R, Ziyaeyan M. Determining major genotypes of hepatitis C virus among transplant recipients by real-time polymerase chain reaction assay. Jundishapur J Microbiol 2015;8(2):e16722.
13. Salehi Moghadam F, Mohebbi SR, Hosseini SM, Romani S, Mirtalebi H, Azimzadeh P, et al. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. J Med Virol 2014;86: 1342-49.
14. Sunbul M, Khan A, Kurbanov F, Leblebicioglu H, Sugiyama M, Tanaka Y, et al. Tracing the spread of hepatitis c virus in turkey: A phylogenetic analysis. Intervirology 2013;56:201-205.
15. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis c virus in iran as reflected by phylogenetic analysis of the ns5b region. J Med Virol 2004;74:246-252.
16. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602.
17. Cavalheiro Nde P, Barone AA, Tengan FM. HCV sero types in brazilian patients. Int J Infect Dis 2002;6:228-232.
18. De Cock L, Vranckx R. Serotyping and genotyping of hepatitis c virus in Belgium. Infection 2003;31:92-97.
19. Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, et al. U.S. Multicenter pilot study of daily csensus interferon (cifn) plus rib avirin for "Diffcult-to-treat" Hcv genotype 1 patients. Dig Dis Sci 2011;56:880-888.
20. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of in fection with hepatitis c virus. The hencore group. Hep atitis c european network for cooperative research. Lan cet 1999;354:2119-2124.
21. Yoon SK, Han JY, Pyo CW, Yang JM, Jang JW, Kim CW, et al. Association between human leuko cytes antigen alleles and chronic hepatitis c virus ifetion in the korean population. Liver International 2005; 25:1122-1127.
22. Matsumori A. Role of hepatitis c virus in cardiomyop athies. Ernst Schering Res Found Workshop 2006:99-120.
23. Shichi D, Matsumori A, Naruse TK, Inoko H, Kimura A. HLA-DQB chain may confer the susceptibility to hepatitis c virus-associated hypertrophic cardiomyopathy. Int J Immunogenetics 2008;35:37-43.
24. Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis c viral load. Hepatology 2001;33:224-230.
25. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis c virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.